Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucinex Fast-Max Cold & Flu All-in-One is a multi-symptom, over-the-counter combination medication developed and marketed by Reckitt. This maximum-strength formulation is designed to address nine common cold and flu symptoms through the synergistic action of four active ingredients: acetaminophen (analgesic/antipyretic), dextromethorphan HBr (antitussive), phenylephrine HCl (nasal decongestant), and guaifenesin (expectorant). It is primarily indicated for the temporary relief of cough, nasal and chest congestion, sore throat, headache, minor aches and pains, and fever. The product is typically available as an oral liquid solution and is intended for use in adults and children 12 years of age and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mucinex Fast-Max Cold & Flu All-in-One.